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KERENTANAN DAN MEKANISME KERINTANGAN YANG 
MUNGKIN BAGI LINEZOLID DALAM KALANGAN MRSA YANG 
DIISOLAT DARI DUA HOSPITAL AWAM UTAMA DI MALAYSIA 
ABSTRAK 
Linezolid merupakan antibiotik pertama dari kelas struktur baru, 
oksazolidinon, yang telah diluluskan untuk kegunaan klinikal setelah 35 
tahun. Ejen anti-mikrob ini berkesan secara meluas terhadap patogen gram-
positif rintang-antibiotik yang sering menjadi punca jangkitan bakteria. 
Walau bagaimanapun, kewujudan ubat ini di hospital-hospital kerajaan 
Malaysia adalah agak rendah dan maklumat mengenai keberkesanan linezolid 
dalam rawatan MRSA adalah kurang memadai. Objektif kajian ini adalah 
untuk menyiasat sensitiviti terhadap linezolid dalam kalangan Staphylococcus 
aureus rintang-metisilin (MRSA) di Malaysia. Berasaskan 100 isolat-isolat 
yang dikumpulkan dari dua hospital kerajaan iaitu Hospital Universiti Sains 
Malaysia (HUSM) dan Hospital Pulau Pinang (HPP), didapati bahawa semua 
isolat MRSA klinikal adalah sensitif terhadap linezolid dengan sepenuhnya. 
Sensitiviti terhadap 5 antibiotik lain yang turut dikaji untuk 100 isolat-isolat 
tersebut. Tiga isolat dari HPP menunjukkan kadar rintangan perantaraan 
untuk vankomisin dengan nilai MIC 3 - 8μg/ml, 4% daripada isolat-isolat 
MRSA klinikal adalah rintang terhadap kloramfenikol, 20% adalah rintang 
terhadap klindamisin, 33% adalah rintang terhadap eritromisin dan kesemua 
isolat adalah rintang terhadap oksasilin (menurut definisi mikrobiologi 
MRSA). Akhirnya, kewujudan mekanisme molekul yang boleh menyumbang 
kepada kerintangan terhadap linezolid juga telah dikaji. Kaedah yang paling 
biasa MRSA memperoleh kerintangan terhadap linezolid iaitu penggantian 
bes G2576U dalam RNA 23S ribosom, adalah ternyata tidak ditemui dalam 
 xv 
 
mana-mana isolat. Pemerolehan gen kerintangan, cfr, yang mengkodkan 
enzim Cfr metiltransferase, boleh menyebabkan kerintangan terhadap 
linezolid. Walau bagaimanapun, kehadiran gen ini dalam komposisi genetik 
MRSA klinikal tidak dapat dikesan dalam analisis gel agaros dari kaedah cfr-
PCR yang dijalankan dalam kajian ini. Kaedah penjujukan DNA telah 
mengenal pasti sejumlah 26 jenis penggantian dan sejenis penghapusan bes 
yang terdapat dalam domain V 23S rRNA yang diasingkan dari 11 isolat-
isolat MRSA klinikal. Berdasarkan pada data-data yang dikumpulkan dalam 
kajian ini, linezolid disyorkan sebagai alternatif yang sesuai kepada 
vankomisin untuk rawatan jangkitan MRSA di dalam persekitaran hospital di 
Malaysia. 
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LINEZOLID SUSCEPTIBILITY AND POTENTIAL RESISTANCE 
MECHANISMS AMONG MRSA ISOLATED FROM TWO MAJOR 
PUBLIC HOSPITALS IN MALAYSIA 
ABSTRACT 
Linezolid is the first antibiotic of a new structural class, the 
oxazolidinones, to be approved for clinical use in 35 years. This antimicrobial 
agent is broadly effective against drug-resistant gram-positive pathogens 
which commonly cause infections. However, the availability of this drug in 
Malaysian government hospitals is relatively low and the knowledge on 
linezolid‘s efficacy in MRSA treatment is lacking. The objective of this 
research was to determine the susceptibility towards linezolid among 
methicillin-resistant Staphylococcus aureus (MRSA) in Malaysia. From the 
100 strains collected from two government hospitals, namely Hospital 
Universiti Sains Malaysia (HUSM) and Hospital Pulau Pinang (HPP), it was 
found that all clinical MRSA isolates were fully susceptible to linezolid. The 
susceptibilities of 100 isolates against 5 other antibiotics were also studied. 
Three strains from HPP showed intermediate vancomycin resistance with 
MICs of 3-8µg/ml, 4% of clinical MRSA were resistant to chloramphenicol, 
20% were resistant to clindamycin, 33% were resistant to erythromycin and 
all were resistant to oxacillin (as per microbiological definition of MRSA). 
Finally, the presence of molecular mechanisms conferring linezolid resistance 
was investigated. The most common way through which MRSA acquires 
resistance to linezolid, the G2576U base substitution at 23S ribosomal RNA, 
was noticeably absent in all isolates. Acquisition of a natural resistance gene, 
cfr, which encodes for the Cfr methyltransferase enzyme, could render 
 xvii 
 
resistance to linezolid. However, the presence of this gene in the genetic 
makeup of clinical MRSA was not detected according to agarose gel analysis 
of cfr-PCR conducted in this study. DNA sequencing revealed a total of 26 
types of base substitutions and one type of base deletion within domain V of 
23S rRNA of 11 clinical MRSA isolates. Based on data accumulated in this 
study, linezolid is recommended as an acceptable alternative to vancomycin 
for MRSA infections treatment in Malaysian healthcare settings. 
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CHAPTER 1 
INTRODUCTION 
1.1  PROBLEM STATEMENT 
Methicillin-resistant Staphylococcus aureus (MRSA) infections constitute an 
important and still evolving global health challenge. The highly pathogenic 
MRSA readily acquires resistance against most classes of antibiotics through 
gene conversion (mutation) or horizontal transfer of resistance genes from other 
bacteria. Methicillin resistance  is clinically important since it renders MRSA 
resistant against many members of drugs within the commonly prescribed ß-
lactam family of antibiotics (Grundmann, Aires-de-Sousa, Boyce, & Tiemersma, 
2006). Colonized or infected MRSA-positive patients are major reservoirs for 
this microorganism while transitory carriage of this pathogen on the hands of 
healthcare workers is the most common mechanism of transmission from 
patient-to-patient in hospital settings (Bertrand et al., 2012).  
According to a 2009 health report published by the Malaysian Ministry of 
Health, the prevalence of MRSA infections in Malaysia was the highest in Kuala 
Lumpur General Hospital (KLGH) at 28.5% and it was followed closely by 
Penang General Hospital (PGH) at 28% (Institute for Medical Research, 2010). 
It is a worrisome situation in hospitals to record a high number of MRSA 
incidence. MRSA are often resistant to a number of antibiotics which leads to 
increased morbidity and mortality in nosocomial infections (Wunderink et al., 
2012).  
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Vancomycin has been used for MRSA treatment for the past 40 years since 
1958 due to its efficacy in eradicating this ‗superbug‘ (Wilhelm & Estes, 1999). 
However, in 1997, the very first vancomycin-intermediate-resistant S. aureus 
(VISA) was reported in Japan (Hiramatsu et al., 1997). The emergence of 
vancomycin-resistant S. aureus (VRSA) due to horizontal gene transfer of vanA 
which confers resistance towards high concentrations of vancomycin in 
vancomycin-resistant enterococci (VRE) demonstrates complete vancomycin 
resistance (Chang et al., 2003).  
The American Food and Drug Administration (FDA) approved the first 
oxazolidinone antibiotic, linezolid, in April 2000 for the treatment of MRSA. 
Since then, this antibiotic has been used to treat a multitude of serious infections 
caused by MRSA with an optimum amount of success (Watkins, Lemonovich, & 
File, 2012). The use of linezolid to treat MRSA will eventually reduce the 
pressure on excessive vancomycin usage (Dennis L. Stevens et al., 2002). 
However, resistance towards linezolid was reported as soon as it was deployed 
for use in the clinical setting. The first resistant strain was isolated from the 
peritoneal fluid of an 85-year-old man undergoing linezolid therapy for 
peritonitis (Tsiodras et al., 2001). Since then, linezolid-resistant MRSA strains 
have been reported worldwide even though the emergence of resistance towards 
linezolid remains very rare (Ikeda-Dantsuji, Hanaki, Nakae, et al., 2011).  
This is the first study that will report and characterise linezolid sensitivity 
among nosocomial MRSA strains isolated from Penang General Hospital in 
Pulau Pinang (PGH) and Hospital Universiti Sains Malaysia (HUSM) in 
Kelantan, Malaysia. Three methods to investigate linezolid resistance were 
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carried out. These surveillance methods will be further discussed in detail in 
upcoming chapters. 
1.2  GENUS STAPHYLOCOCCUS 
Staphylococcus literally means ―a bunch of grapes‖ in the Greek language 
and this name was first introduced by a 19
th 
century surgeon, Sir Alexander 
Ogston in 1883 when a group of micrococci was studied for causing 
inflammation and pus formation. The name was derived as such due to the 
bacteria‘s cocci and grape-like cluster appearance when viewed under the 
microscope. The genus was formally described in 1884 by Friedrich Julius 
Rosenbach and he further classified the genus into two separate species 
Staphylococcus aureus and Staphylococcus albus (now known as 
Staphylococcus epidermidis) (Jones & Niven, 1964). 
As of 2009, there are more than 50 species and subspecies of this genus 
which have been greatly described and characterised in length. However, the 
most prominent member of this genus is Staphylococcus aureus which is a 
notorious human-infecting pathogen (Ng et al., 2009). Members of this genus are 
Gram-positive, a classification due to its significantly thick peptidoglycan layer 
which is a trademark of all Gram-positive prokaryotes (Cummins & Harris, 
1956). Their unusual ‗bunch of grapes‘ formation is due to incomplete binary 
fission which enables them to multiply in more than one axis. The approximate 
size of this coccus is 0.5 – 1.5µm in diameter. They are all non-motile, non-
sporulate and have limited capsule forming ability or are non-encapsulated 
altogether. All members of this genus are catalase-positive, where they are able 
to convert harmful reactive oxygen species (ROS) to water and oxygen to 
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prevent oxidative damage. They are also facultative anaerobic microorganisms 
(able to conduct aerobic respiration in the presence of oxygen and also capable 
of fermentation using glucose), able to ferment mannitol to produce acidic by-
products, have a G + C DNA composition of 33 – 39 mol% and genome size in 
the range of 2 to 3Mb (Baird-Parker, 1963; Evans, 1947; Götz, Bannerman, & 
Schleifer, 2006).  
Some of the well-known members of this genus include S. aureus, S. 
epidermidis, S. saprophyticus, S. haemolyticus and S. hominis. These species are 
human pathogens however the first two species are more commonly isolated 
amongst clinical samples. Stapylococcal infections often result from 
transmission of this bacterium from an infected person to a susceptible 
individual who may remain asymptomatic. Both of the mentioned species 
recurrently exist as normal flora of the upper respiratory tract and often reside on 
the skin without causing any harm. Nevertheless, staphylococci may cause a 
variety of skin infections including boils, acne and impetigo as well as 
pneumonia, meningitis and osteomyelitis. Many staphylococcal diseases cause 
pus formation in patients and thus staphylococci are referred to as pyogenic. 
Even though the majority of staphylococcal carriers remain asymptomatic for 
most of their lifetime, serious infections may surface when immunological status 
of human host fluctuates due to underlying disease or aging processes (Madigan, 
Martinko, Paul, & Clark, 2009).  
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1.3 STAPHYLOCOCCUS AUREUS 
1.3.1 Characteristics  
Staphylococcus aureus is perhaps the most common causative agent of skin 
infections because humans serve as a natural reservoir of this bacterium. It has 
been reported that almost 30 - 50% of healthy adults are carriers of S. aureus 
with 10 - 20% being persistent carriers (Lowy, 1998). Colonisation with S. 
aureus increases one‘s risk of developing nosocomial infections and up to 30% 
of nosocomial infections have been reported to be due to colonisation with this 
microorganism (Bloemendaal et al., 2009). 
S. aureus often express various cell surface-associated and extra-cellular 
proteins which may function as potential virulence factors. These factors enable 
adherence to the host cell while other factors allow the bacterial invasion 
through evasion of the host immunological response. Fibronectin-binding 
proteins, collagen-binding proteins, staphylococcal protein A and clumping-
factors target components of the human extracellular matrix such as collagen, 
fibronectin and fibrinogen to initiate staphylococcal infections (Foster, 1996). 
Exoproteins are secreted by S. aureus to alter host tissues into nutrients that are 
essential for bacterial growth thus causing disease in mammalian hosts, mainly 
humans. This includes proteases, lipases, nucleases, hyaluronidases and 
collagenases which are secreted by almost all strains of S. aureus (Justyna Bien, 
Olga Sokolova, & Przemyslaw Bozko, 2011). Exotoxins such as α-hemolysin, β-
hemolysin, γ-hemolysin are known to possess cytolytic activities where the 
secreted toxins form pores in the plasma membrane and cause cell lysis. Alpha-
hemolysin has been reported to be particularly cytolytic towards human platelets 
and monocytes (Dinges, Orwin, & Schlievert, 2000). Pathogenesis of 
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staphylococcal disease is multifactorial and the disease manifests due to the 
simultaneous production of several virulence factors and therefore the precise 
role of exotoxins excreted by S. aureus is difficult to be determined (Bhakdi & 
Tranum-Jensen, 1991). However, the correlations found between strains that 
have been isolated from a particular disease and the increased expression of 
certain proteins within these strains aid in unveiling their importance in 
pathogenesis (Foster, 1996).  
1.4 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS 
1.4.1 Epidemiology 
  The first emergence of methicillin-resistant Staphylococcus aureus (MRSA) 
was reported in United Kingdom hospitals in 1961, where a large sample pool 
derived from surrounding hospitals was tested for any occurrence of resistance 
towards the then new penicillinase-resistant penicillin called ‗celbenin‘ (Jevons, 
1961). ‗Celbenin‘ was another name for methicillin produced by Beecham 
Research Laboratories in 1959 for battling against staphylococcal penicillinase 
which compromised the use of penicillin for treating infections caused by 
staphylococci (Çetin & Ang, 1962; Montgomery, 1962). MRSA belongs to the 
species of Staphylococcus aureus and it is the antibiotic-resistant form of the 
mentioned species but more pathogenic (Gordon & Lowy, 2008).  
  Up to date, two groups of MRSA have been identified. They comprise 
hospital-acquired MRSA (HA-MRSA) and community-acquired MRSA (CA-
MRSA) (Enright, 2006).  This study is associated with HA-MRSA since our 
isolates are derived from two hospitals in Malaysia. HA-MRSA is globally 
distributed and it is the leading cause of nosocomial infections reported 
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throughout the world (Maple, Hamilton-Miller, & Brumfitt, 1989). After the first 
emergence of HA-MRSA in 1961, this pathogen spread rapidly and successively 
and now creates tremendous problems in hospital settings which are associated 
with increased treatment cost and prolonged hospital stay (Mulligan et al., 1993).  
  This opportunistic pathogen usually infects individuals who have 
compromised immune response or chronic diseases like diabetes mellitus or 
breached epithelial surfaces of the body such as broken skin. MRSA infections 
in humans cause a great number of illnesses such as septicaemia, skin and soft 
tissue infections (SSTIs), pneumonia, toxic shock syndrome and endocarditis 
(Moran et al., 2006; Sandlin, 2008). Ailments such as necrotising fasciitis and 
necrotising pneumonia also evolve from SSTIs (Morgan, 2011).  
  Not all MRSA infections cause illness or most importantly show symptoms. 
It may colonize areas in the human body such as the respiratory tract, nasal 
cavity and urinary tract but the patient remains asymptomatic. These infected 
individuals are known as carriers and they are one of the reasons for MRSA 
dispersal in hospital settings through nursing contact (Wenzel, Nettleman, Jones, 
& Pfaller, 1991). Patients admitted to the intensive care unit are often at high 
risk of MRSA exposure due to invasive procedures carried out in the unit. 
Medical apparatus including intravenous catheters, open surgical wounds, 
excessive use of antibiotics and prolonged hospital stay clearly multiply the 
chances of MRSA colonization and infection (Coello, Glynn, Gaspar, Picazo, & 
Fereres, 1997). In some cases, enteral feedings too pose an increased risk of 
infection as it may serve as a route of entry for the pathogen. It may be due to the 
tainted nutrition solution or contaminated feed tube caused by a greater number 
of handlings during the administration or assembly of the food duct (Graffunder 
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& Venezia, 2002). This certainly emphasizes the use of aseptic intravenous 
tubes, hand sanitization and early catheter removal to reduce MRSA epidemics 
worldwide. An improvement of 12% in hand hygiene routine was predicted to 
have compensated for staff shortage in intensive care units and prevented MRSA 
transmission during the times of high workload and patient overcrowding 
(Grundmann, Hori, Winter, Tami, & Austin, 2002). 
  Previous antibiotic therapy is associated with colonisation or infection with 
MRSA. It was documented that 80% of nosocomial bacteraemia will be resistant 
towards methicillin if any one type of antibiotic was used for treatment more 
than once in the patient‘s past medical history and regardless of the antimicrobial 
agent, patients will be predisposed to MRSA (Lodise, Peggy S. McKinnon, & 
Rybak, 2003). Due to excessive usage of unnecessary antibiotics in the United 
States, the Society for Healthcare Epidemiology of America (SHEA) reported 
that this situation creates a competitive advantage for the bacteria through 
development of resistance. They further suggested a reduction in the use of 
antibiotics especially fluoroquinolones to decrease the persistent carriage of 
MRSA (Muto et al., 2003). It was also noted that the higher the proportion of 
colonised patients in an intensive care unit, the higher are the chances of 
contracting MRSA regardless of the unit size (Tacconelli, De Angelis, Cataldo, 
Pozzi, & Cauda, 2008).  
Prior hospitalisation has been determined as a risk factor in acquiring MRSA 
infections or colonisation. All patients who were included in a prospective study 
at the time of admission for being MRSA positive had been previously admitted 
to a hospital in the previous year (Lodise et al., 2003). In another report, 
residents of a nursing care facility were found to be colonised with this pathogen 
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due to hospital admission and this factor was found to be the most important 
marker for positive infection (Warshawsky et al., 2000).  
  Patients with diabetic foot ulcers are susceptible to MRSA infection due to 
peripheral arterial disease and have poor penetration of antibiotics to lower limb 
tissues. This situation presents an excellent niche for MRSA to breach the 
broken skin barrier of the patient thus causing a full-fledged infection 
(Raymakers et al., 2001). It was noted that MRSA infection in diabetic foot 
ulcers was reported to occur in 18% of total patients with this disease and 
previous hospitalisation for the same condition and cross transmission from the 
hands of care-givers  may have contributed to this circumstance (Hartemann-
Heurtier et al., 2004).  
  It has been reported that MRSA transmission from colonized patients or 
healthcare workers to their household contacts are as high as 47% and it can be 
said that the spread of the infection happens in nearly half of all cases studied. 
One more intriguing fact is that once the infection happens in a household, 
nearly two-thirds of the house population will be MRSA positive carriers 
(Mollema et al., 2010). Besides direct contact transmission, there are cases 
which demonstrate that the environment of the MRSA positive person such as 
door knobs, bathroom sinks, light switches and remote controls may serve as the 
source of spreading for the household members to be positively colonized with 
this pathogen (Uhlemann et al., 2011). 
  Simple daily acts of respiratory secretions including sneezing, coughing and 
even kissing would definitely play a contributory action of disseminating MRSA 
into the environment. It is not only important to swab bacterial samples from 
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anterior nares alone but the throat too must be scrutinised for colony 
establishment (Snyder et al., 2008). The proximity between the household 
contact and the MRSA positive person too determines the risk of contraction, the 
risk being higher if linens are shared and frequent body contact is displayed 
(Hall, Bixler, & Haddy, 2009). 
  The increasing transmission of MRSA in health care settings has prompted 
the use of infection control gowns and gloves which are required to be worn by 
healthcare workers. A related study demonstrated that MRSA strains were 
frequently isolated from these gowns and gloves and the detection frequency was 
18% but it is important to note that even after removal of these protective 
barriers, it was found that MRSA was acquired by these healthcare workers 
especially on their hands (Snyder et al., 2008). 
1.4.2   ß-lactam antibiotic resistance mechanism 
  Wild type S. aureus strains have 4 penicillin-binding proteins (PBPs) which 
are anchored on the cytoplasmic membrane that take part in the cross-linking of 
peptidoglycan layer which constitutes the bacterial cell wall. These PBPs have 
high affinity towards ß-lactam agents which bind and halts the assembly of the 
bacterial cell wall leading to cell death (Palavecino, 2007). All MRSA strains 
which are examined so far are known to contain the mecA gene, the causative 
agent of methicillin resistance in this pathogen. This gene has been identified to 
encode a 78 kDa protein called penicillin-binding protein 2A (PBP2A). PBP2A 
has a decreased affinity towards ß-lactam antibiotics and the protein only gets 
activated when staphylococcal PBPs are bound to the ß-lactam antibiotics in the 
medium and are unable to synthesise peptidoglycan. PBP2A has been proven to 
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take over the synthesis of peptidoglycan when the antibiotic threshold level 
reaches 5µg/ml (de Jonge & Tomasz, 1993).   
However, the mecA gene is not exclusively found in Staphylococcus aureus 
but also in another species known as Staphylococcus sciuri (Wu, de Lencastre, & 
Tomasz, 2001). This bacterium is often found as a commensal on the skin of 
rodents and primitive mammals. It is also described as a relatively rare 
microorganism to be found in humans (Couto, Wu, Tomasz, & de Lencastre, 
2003). The mecA gene is located on a mobile genetic element called 
staphylococcal cassette chromosome (SCC) which is widely dispersed among 
staphylococci and primarily causes methicillin-resistance when acquired by a 
susceptible strain (Katayama, Zhang, Hong, & Chambers, 2003). This element 
incorporates into the S. aureus chromosome at a specific location called attB scc 
which can be found near the origin of replication (de Lencastre, Oliveira, & 
Tomasz, 2007). It is further classified into types and subtypes and it is now a 
customary practice to identify MRSA strains with their SCCmec type (Elements, 
2009). Currently there are 6 types of SCCmec elements that have been 
categorised and typing of MRSA is principally done by PCR fragment analysis 
(Bartels et al., 2013).   
1.5 MRSA TREATMENTS (Disinfectant and antibiotics) 
1.5.1 Chlorhexidine 
‗Prevention is better than cure‘ is always practiced in hospitals when it 
comes to MRSA infection. In this case, decolonization of MRSA is entirely 
necessary in preventing successive infections especially to reduce the rate of 
MRSA infection dispersal in health care and community settings (Buehlmann et 
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al., 2008). A chemical agent called chlorhexidine is largely used as surface 
antiseptic in hospitals and mainly in intensive care units (ICU) to prevent MRSA 
colonization. It has been reported that in a stable 20% prevalence of MRSA in 
ICU wards, the usage of chlorhexidine maintained a reduction in MRSA 
dispersal. There is also evidence that usage of this antiseptic on MRSA carriers 
and all ICU patients is useful in governing MRSA based colonization which 
could have led to subsequent infection (Batra et al., 2010). Another report states 
that daily chlorhexidine-bath for ICU patients have reduced MRSA acquisition 
by 32%. This skin disinfection method is practiced as an improvement of barrier 
protection for the prevention of MRSA transmission from a carrier to a non-
carrier in ICU wards (Climo et al., 2009). 
1.5.2 Mupirocin 
  One decolonizing agent widely used in hospitals throughout the world is 
mupirocin, a topical antibiotic originally isolated from Pseudomonas fluorescens 
NCIMB 10586 when bacterial inhibition activity was observed towards S. 
aureus (NCTC 6571) (Fuller et al., 1971) . This antimicrobial agent has been in 
use since the 1980s to eradicate S. aureus in the nasal cavity based on the notion 
that S. aureus carriers create a higher risk of contracting MRSA infections and 
have higher chances of transmitting it to other patients or healthcare workers 
through contact (Parras et al., 1995; Rode, Hanslo, de Wet, Millar, & Cywes, 
1989). Completion of mupirocin treatment has been shown to reach almost 
81.5% to 100% of MRSA colony eradication and only in rarer conditions the 
success level was 6% due to poor patient compliance (Coates, Bax, & Coates, 
2009).   
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1.5.3 Trimethoprim-Sulfamethoxazole (TMP-SMX) 
Oral antibiotics are typically used to treat skin and soft tissue infections 
(SSTI) in the hospitals and where S. aureus is the causative agent of SSTIs 
including boils, carbuncles, abscesses and surgical site infections. A 33% death 
rate is associated with MRSA-caused SSTIs and 16% for MSSA-caused SSTIs 
(Wolk et al., 2009). Trimethoprim-sulfamethoxazole (TMP-SMX) is one of the 
common oral antibiotics often prescribed along with other antimicrobial drugs to 
combat MRSA causing SSTI (Cadena et al., 2011). This drug is well tolerated, 
offers better penetration into tissues and most importantly it is an economical 
and effective treatment against SSTIs caused by MRSA (Goldstein & Proctor, 
2008).  
1.5.4 Daptomycin (Cubicin) 
Daptomycin is a cyclic lipopeptide antibiotic reported as a promising 
treatment against MRSA infections particularly complicated skin and skin 
structure infections (cSSSIs) which was approved for use in the United States 
since 2003. It inhibits bacteria through bactericidal activity and has a broad 
spectrum of activity against most Gram-positive bacteria (French, 2006; Rybak, 
2006). It is often used as a second-line therapy after a glycopeptide or an 
oxazolidinone antibiotic. This drug is widely preferred as a prolonged treatment 
option in cases of endovascular or osteoarticular infections due to toxicity 
concerns which arise with the use of its counterparts (Gonzalez-Ruiz et al., 
2011).  
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1.5.5 Quinupristin-Dalfopristin (Synercid) 
  Quinupristin and dalfopristin are streptogramin antibiotics which, used in 
combination, act together to bind to different sites on the large bacterial 
ribosomal subunit to inhibit protein synthesis synergistically. The first injectable 
streptogramin antibiotic, it demonstrates consistent in vitro activity against 
MRSA (Drew et al., 2000). This antibiotic has been used in cases where 
vancomycin therapy failed in invasive MRSA infections. However, due to side 
effects of myalgias and arthralgias (muscle and joint pains), its usage in MRSA 
treatment is limited (Saravolatz & Eliopoulos, 2003). It has also been reported 
that quinupristin-dalfopristin does not show superior efficacy over vancomycin 
or ß-lactam antibiotics in any clinical trial (Anstead, Quinones-Nazario, & 
Lewis, 2007).  
1.5.6 Rifampin 
  Rifampin was first approved for tuberculosis treatment in 1971, and due to 
its low toxicity, its use has expanded towards staphylococcal infections 
especially those caused by S. aureus where is it used in combination with 
another antibiotic, which is active against staphylococcus, for better eradication 
(Forrest & Tamura, 2010). This drug offers potent bactericidal activity and it is 
able to penetrate cells and certain tissues especially when used as adjunctive 
treatment together with vancomycin (Deresinski, 2009). However, the role of 
this antibiotic as a combination therapy for MRSA has not been well established 
due to a shortage of clinical trials in the literature (Liu et al., 2011).  
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1.5.7 Telavancin (Vibativ) 
  Telavancin is a lipoglycopeptide with rapid bactericidal activity which 
functions by more than one mechanism, including inhibition of bacterial cell 
wall synthesis and disruption of bacterial membrane function which eventually 
results in bacterial death. It is also active against almost all gram-positive 
bacteria including MRSA (Stryjewski et al., 2008). However, it can only be 
administered via the parenteral route just like its glycopeptide counterpart, 
vancomycin. Telavancin‘s improved potency and bactericidal activity have 
prompted its approval for its use in treating complicated skin and skin structure 
infections (cSSSIs) especially those caused by pathogenic MRSA (Saravolatz, 
Stein, & Johnson, 2009).   
1.5.8 Vancomycin (Vancocyn) 
Vancomycin belongs to the antibiotic class of the glycopeptides and has a 
molecular weight of approximately 1500 Daltons. It is the drug of choice for 
severe infections caused by MRSA and is also the drug of choice for patients 
who are allergic to penicillins or cephalosporins (Wilhelm & Estes, 1999). This 
compound inhibits the synthesis of peptidoglycan, the major structural polymer 
of the bacterial cell wall where it disrupts the second stage of peptidoglycan 
synthesis at a site earlier than the targeted location of penicillin thus offering no 
chance of cross-resistance to occur (Reynolds, 1989).  
Since its first use in 1958, this drug has been the drug of choice for treating 
gram-positive bacterial infections when all other antibiotics have failed. It was 
not until more than 3 decades later that the very first intermediately vancomycin-
resistant Staphylococcus aureus (VISA) was discovered in Japan (Hiramatsu et 
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al., 1997). Modified cell expression of several marked genes and thickened cell 
wall due to genetic mutation have prevented vancomycin from reaching its target 
(Sievert et al., 2008). Horizontal gene transfer of vanA from vancomycin-
resistant Enterococci (VRE) to MRSA has brought upon a new category of S. 
aureus strains called vancomycin-resistant S. aureus (VRSA) which 
demonstrates complete vancomycin resistance (Chang et al., 2003).  
Its efficacy has come into question due to its slow bactericidal activity, poor 
tissue penetration and the increasing occurrence of ‗MIC creep‘. The latter term 
means there is a an observation of S. aureus‘s MIC value experiencing a gradual 
increase against vancomycin treatment (Deresinski, 2007). Vancomycin has 
been compared to other newer antibiotics in a variety of randomised clinical 
trials. In a major trial which compared the efficacy of vancomycin and linezolid 
for bacterial eradication in cSSSIs caused by MRSA, linezolid performed better. 
The clinical trial found that linezolid treatment had 88.6% eradication of MRSA 
compared to vancomycin therapy‘s 66.9% (Weigelt et al., 2005).   
1.5.9 Linezolid (Zyvox) 
Emergence of microorganisms with reduced susceptibility towards 
vancomycin has necessitated the need for a new agent for our defence against 
MRSA (Caffrey, Quilliam, & LaPlante, 2010). Linezolid, an oxazolidinone 
antibiotic was first approved for use in April 2000 by the American Food and 
Drug Administration. This novel agent is the first in its class to prevent 
formation of the initiation complex (70S) by selectively binding to 23S 
ribosomal RNA at the peptidyl transferase center of the 50S ribosomal unit. The 
Clinical and Laboratory Standards Institute (CLSI) guidelines state that the 
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minimal inhibitory concentration (MIC) value of less than or equal to 4µg/ml is 
the break point for linezolid susceptibility in Staphylococcus spp. and most of 
the Staphylococcus aureus strains including MRSA have been found to be 
susceptible towards linezolid (Ikeda-Dantsuji, Hanaki, Nakae, et al., 2011). 
Linezolid inhibits bacterial protein translation (Beibei et al., 2010). There is 
less chance for cross resistance to occur because the other protein synthesis 
inhibitors such as tetracyclines, aminoglycosides and macrolides often interferes 
in the elongation step of protein synthesis, which occurs much later in the 
protein synthesis process while linezolid inhibits the formation of initiation 
complex itself (Kloss, Xiong, Shinabarger, & Mankin, 1999). This antibiotic is 
bacteriostatic against Staphylococcus spp. and bactericidal against Streptococci 
spp. (Pankey & Sabath, 2004).  
Unlike vancomycin, which has to be given only intravenously due its poor 
oral absorption rate and in frequently adjusted doses due to high nephrotoxicity, 
linezolid is 100% bioavailable in its oral form. It is available in the form of a 
tablet (400 and 600 mg), oral suspension (100 mg/5 ml) and a ready-to-use 
intravenous formulation (200 mg/100 ml and 600 mg/300 ml) (D. L. Stevens, 
Dotter, & Madaras-Kelly, 2004). The availability of linezolid‘s oral form 
accommodates switching of drug administration either parental or orally during 
the course of treatment without any changes to the drug dosage (Beringer et al., 
2005; Welshman, Sisson, Jungbluth, Stalker, & Hopkins, 2001; Wunderink, 
Rello, Cammarata, Croos-Dabrera, & Kollef, 2003). Oral administration of 
linezolid compared to intravenous administration of vancomycin seems to have 
reduced the number of catheter-related infections. MRSA infected patients are 
usually switched from linezolid by intravenous route to oral administration 
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within 5 days of initial therapy. The usage of linezolid to treat MRSA will 
eventually reduce the pressure on excessive vancomycin use (Dennis L. Stevens 
et al., 2002).  
A prospective, randomised and double blind multicentre trial comparing the 
efficacy of linezolid treatment in pneumonia caused by MRSA reports that the 
success rate for linezolid therapy was 57.6% and 46.6% for vancomycin therapy 
(Wunderink et al., 2012). The microbiological outcome collected from the 
respiratory sample in the trial showed 17% of cultures positive for MRSA in 
linezolid-treated patients and 46% for patients who received vancomycin. 
Besides that, a higher rate of nephrotoxicity was recorded for patients who 
received vancomycin (18.2%) than linezolid (8.4%) (Watkins et al., 2012).  
In cases of SSTIs caused by MRSA, another randomised and controlled 
study has reported that linezolid treatment was well tolerated and the outcome 
was similar with vancomycin in treating the infections (Weigelt et al., 2005). 
Patients with proven MRSA SSTIs experienced a shorter length of hospital stay, 
better microbiological outcome and reduced duration of intravenous therapy 
when treated with linezolid compared to the patients treated with vancomycin 
(Itani, Biswas, Reisman, Bhattacharyya, & Baruch, 2012).  
Osteomyelitis is often a tricky condition to treat due to the poor penetration 
of antibiotics into bone. In usual clinical practice, antibiotics are often prescribed 
for longer courses such as 6 to 8 weeks. However, linezolid is normally not 
prescribed for more than 4 weeks due its adverse effects of causing bone marrow 
suppression with long term usage (Liu et al., 2011). In a retrospective chart-
review study which was conducted for 13 weeks where MRSA was the primary 
pathogen in osteomyelitis infection, a 79% cure-rate was recorded for linezolid 
 19 
 
treatment even though 51.5% of patients reported adverse events during the 
treatment duration (Senneville et al., 2006).    
One of the most common infections encountered by diabetic patients is 
diabetic foot infections (DFI). MRSA has become the most frequently occurring 
pathogen causing DFIs. Prevalence of this pathogen was found to be between 
5% to 30% in a study conducted from year 1997 to 2007 (Eleftheriadou, 
Tentolouris, Argiana, Jude, & Boulton, 2010). Previous hospitalisation, 
excessive or inappropriate usage of antibiotics, prolonged duration of the foot 
wound and presence of osteomyelitis are some of the risk factors which prompts 
MRSA infections on the diabetic foot wounds (Liu et al., 2011). A previous 
randomised study reported that the clinical cure rate for linezolid-treated patients 
was 81% compared to 68% for patients treated with ampicillin-sulbactam or 
amoxicillin-clavunate in patients with infected foot ulcers. Whereas in patients 
without osteomyelitis, cure rate was 87% in linezolid-treated condition and 72% 
in patients treated with aminopenicillin/ß-lactamase inhibitors (Lipsky, Itani, 
Norden, & Group, 2004).  
According to the clinical practice guidelines for MRSA treatment by the 
Infectious Disease Society of America (IDSA) published in year 2011, the usage 
of linezolid is recommended as an initial or alternative therapy for pneumonia, 
SSTIs, brain abscess, subdural empyema, spinal epidural abscess, septic arthritis, 
osteomyelitis, meningitis  and septic thrombosis of the cavernous or dural 
venous sinus (Liu et al., 2011). Either linezolid or vancomycin was 
recommended by the American Thoracic Society and IDSA for treatment of 
hospital-acquired pneumonia, ventilator-associated pneumonia and healthcare-
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associated pneumonia which was proven to be MRSA-infected (American 
Thoracic Society & Infectious Disease Society of America (IDSA), 2005).  
The inclusion of linezolid as a treatment option in clinical practice guidelines 
proves that this drug is a valuable addition to the treatment for MRSA in the ever 
increasing resistance towards antibiotics. Although many linezolid-treated 
patients tolerate it well, caution should always be practiced by physicians where 
rare but serious adverse side effects of linezolid including anaemia, 
thrombocytopenia, peripheral neuropathy and optic neuritis could be experienced 
by patients in the event of over-dosage or prolonged usage (Watkins et al., 
2012). 
1.6 MECHANISMS OF LINEZOLID RESISTANCE 
Increasing resistance towards antibiotics used to combat Gram-positive 
bacterial infections has prompted the need for new antibiotics which do not share 
the same mechanism of action as traditional antibiotics thus limiting the chances 
of cross resistance from occurring (D. L. Stevens et al., 2004). One such 
antibiotic is linezolid, the first of the oxazolidinones approved for treating 
MRSA infections. The synthetic nature of this antimicrobial meant that 
resistance was expected to occur only rarely in Staphylococcus aureus mainly 
through spontaneous mutations (Eliopoulos, Meka, & Gold, 2004).  
1.6.1  Ribosomal resistance 
(i) Point mutations in the peptidyl transferase center of 23S rRNA 
A study conducted in year 1999, just before the approval of linezolid for 
clinical usage found that all laboratory-derived linezolid-resistant mutants of 
Halobacterium halobium had single point mutations in 23S ribosomal RNA 
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(rRNA). Seven of the mutations which originate from six different positions 
were localised in the central loop region of domain V in 23S rRNA, where the 
peptidyl transferase center (PTC) is situated, suggesting that possible linezolid  
mutations in clinical settings was more likely to originate from point mutations 
at linezolid target area in PTC (Kloss et al., 1999) (Figure 1.1).  
Linezolid resistance mechanisms among Gram-negative bacteria have been 
investigated in E. coli which contained a randomly mutagenized plasmid-borne 
rRNA operon. Five linezolid resistant mutants were isolated with mutation 
G2032A found in all of the isolates. Engineered mutation of G2032A, G2032U 
and G2447U in the same microorganism rendered linezolid resistance at a high 
concentration (Xiong et al., 2000).  
Mycobacterium smegmatis is a useful model for ribosome-drug interaction 
studies due its resemblance to other Gram-positive pathogenic bacteria. 
However, M. smegmatis with G2032C mutation have only 2-fold increase in 
linezolid MIC compared to 11-fold increase with the same mutation in E. coli 
(Long et al., 2010).   
On the other hand, a G2447U mutation was found to confer linezolid 
resistance in genetically-derived M. smegmatis with a single functional rrn 
operon. Two classes of M. smegmatis mutants were isolated where one class of 
mutants had a uniform G2447U mutation. Changes associated with ribosomes 
were indicated when these class I mutants displayed high level of linezolid 
resistance in vitro for oxazolidinone assays (Sander et al., 2002). Class II 
mutants are described in section 1.6.2.  
In summary, all the linezolid-resistant strains with their respective mutations 
localised to the peptidyl transferase center are shown in Figure 1.1. Apparently,  
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Figure 1.1: Linezolid mutations found in the central loop of domain V in 23S 
ribosomal RNA according to bacterial species. The most common G2576U 
mutation is shown with a bold arrow.  
 
 
 
 
 
E. coli 
A, U 
C   E. coli, M. smegmatis 
E. coli   G 
M. tuberculosis   U 
H. halobium  
C 
E. coli   
A U   E. coli, M. smegmatis, S. aureus, S. epidermidis 
U  M. smegmatis 
U  H. halobium 
U  H. halobium 
C   H. halobium 
C, G   H. halobium 
A   S. aureus, E. coli 
C   H. halobium, S. aureus 
G   M. smegmatis 
A 
 E. faecalis, E.faecium,  
M. smegmatis 
M. smegmatis   U 
S. pneumoniae   G 
U 
C   
U 
S. pneumoniae   A 
E. coli 
S. aureus,   
S. pneumoniae, 
S. epidermidis, 
S. haemolyticus, 
E. coli,               
E. faecalis,        
E. faecium,       
M. smegmatis, 
M. tuberculosis 
 23 
 
these linezolid-resistant strains express various types of mutations that may or 
may not be specific to each of their species alone in contrast to G2576U 
mutation which uniformly causes linezolid resistance in many bacterial species 
as shown in Figure 1.1. 
The very first case of linezolid resistant MRSA in the clinical settings was 
reported in the year 2001 in an 85-year-old patient suffering from dialysis-
related peritonitis in United States of America. It was discovered that the 
resistant MRSA strain isolated from the peritoneal fluid exhibited a G to U 
mutation in position 2576. All three replicates of the original linezolid-resistant-
MRSA isolate showed G2576U mutation in the central loop of domain V in 23S 
rRNA. This spontaneous mutation was believed to emerge from selective 
pressure of linezolid therapy in the patient (Tsiodras et al., 2001).  
The first linezolid resistant MRSA strain in the United Kingdom was 
reported in 2003, where the patient underwent linezolid therapy for thoracotomy 
and drainage of right-sided empyema. This was the second case of linezolid 
resistance in clinical settings worldwide. After 21 days of antimicrobial drug 
treatment, resistant MRSA strain was isolated from a wound swab of the drain 
site and empyema fluid. Again, the G2576U mutation in the central loop of 
domain V in 23S rRNA was detected as in the first case and was also shown to 
be the reason for resistance in this clinical isolate (Wilson et al., 2003). 
As shown in laboratory as well as clinically-linezolid resistant strains, the 
G2576U mutation is the most common mechanism by which MRSA acquires 
resistance towards linezolid. However, it has been demonstrated in vitro that the 
frequency of acquiring linezolid resistance mutations is generally very low, i.e. < 
10
-9 
(Ikeda-Dantsuji, Hanaki, Sakai, et al., 2011).  
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The reason for the rarity of acquiring linezolid resistance via G2576U 
mutation is that Staphylococcus aureus has five or six copies of the ribosomal 
RNA (rrn) operon (Klappenbach, Saxman, Cole, & Schmidt, 2001). This 
mutation is generally dose-dependent, where more than one rrn operon copy is 
needed to be mutated for the bacteria to confer linezolid resistance. Therefore, 
the more number of rrn copies are mutated with this mutation (G2576U), the 
more resistant the bacteria towards linezolid.   
Another interesting finding reported that despite 60 passages in antibiotic-
free medium to eliminate G2576U mutation over a 75-day period, the tested 
linezolid-resistant MRSA isolate, maintained a single copy of mutant 23S rRNA 
(Meka et al., 2004). An existing single copy of mutant 23S rRNA would not 
yield elevated MIC for linezolid detectable by standard laboratory susceptibility 
testing. A case study of G2576U mutation reported that there are possibilities of 
homologous recombination of mutated and non-mutated copies of 23S rRNA of 
Enterococci sp. to survive under selective antibiotic pressure especially in 
hospitals (Marshall, Donskey, Hutton-Thomas, Salata, & Rice, 2002). Therefore, 
linezolid therapy for this type of clinical strains in hospital settings would 
quickly be unsuccessful as gene conversion of G2576U will occur via 
homologous recombination for survival of strain. 
Besides S. aureus, Enterococcus faecalis and Enterococcus faecium have 
been found to utilise the same G2576U mutation to combat linezolid therapy in 
an Austrian hospital. These enterococcal isolates also expressed cross resistance 
towards another experimental oxazolidinone AZD2563, which is still in clinical 
trials, signifying that oxazolidinone resistance might be a class effect of this 
mutation (Johnson et al., 2002). AZD2563 is still in phase II clinical trials and 
